U.S. Markets closed
  • Gold

    +0.80 (+0.05%)

    +0.0007 (+0.0581%)
  • 10-Yr Bond

    +0.0650 (+4.28%)
  • Vix

    +0.01 (+0.06%)

    +0.0019 (+0.1416%)

    -0.1820 (-0.1592%)

    -453.54 (-0.73%)
  • CMC Crypto 200

    -9.68 (-0.67%)
  • FTSE 100

    -30.20 (-0.42%)
  • Nikkei 225

    +187.89 (+0.65%)

Zimmer Biomet (ZBH) Enhances ZBEdge Portfolio With Latest Suite

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Zimmer Biomet Holdings, Inc. ZBH recently introduced the ZBEdge Connected Intelligence Suite of currently available and soon-to-be-launched digital and robotic technologies. Notably, the ZBEdge technologies have been designed to deliver data-powered clinical insights which can be seamlessly shared across the patient’s treatment journey to improve patient outcome.

For investors’ note, the current suite of ZBEdge technologies include the ROSA Robotics Platform as well as remote care and patient engagement management systems like mymobility with Apple Watch, to name a few.

With the latest portfolio enhancement, the company aims to strengthen its musculoskeletal healthcare business across the globe.

Few Words on the ZBEdge Suite

The ZBEdge Connected Intelligence Suite provides hospitals and ambulatory surgery centers access to a robust set of pre-, intra- and post-operative technologies. This leads to an integrated product experience that draws upon data from Zimmer Biomet devices, robotics and digital technologies used throughout each patient's journey of care.

The data thus collected is then aggregated, analyzed and translated into actionable clinical insights to enhance a surgeon's care decisions through the OrthoIntel Orthopedic Intelligence Platform.

Significance of the Launch

Per management, the ZBEdge Connected Intelligence Suite is expected to aid the healthcare professionals to gain better insights between procedural and patient data at every stage of the surgical journey. This will serve the dual purposes of reducing variability of care and enhancing outcomes.

Industry Prospects

Per a report by MarketsAndMarkets, the global medical robots market is expected to reach $12.7 billion by 2025 from an estimated $5.9 billion in 2020 at a CAGR of 16.5%. Factors like advantages of robotic-assisted surgery, growing adoption of surgical robots and technological advancements in robotic systems are expected to drive the market.

Given the market potential, the availability of seamless data-driven intelligence delivery for better treatment decisions and patient outcomes is expected to significantly boost Zimmer Biomet’s business on a global scale.

Recent Developments

Of late, Zimmer Biomet has been witnessing some notable developments across its business.

The company, during its fourth-quarter earnings call in February, confirmed that the reported quarter was the strongest for its ROSA Knee till date since its launch due to its robust performance. Persona Revision portfolio also performed impressively during the quarter.

Further in February, Zimmer Biomet announced its intention to spin off its Spine and Dental businesses to form a new and independent, publicly traded company, NewCo.

In December 2020, Zimmer Biomet announced an exclusive agreement with renowned academic medical center focused on musculoskeletal health, Hospital for Special Surgery (“HSS”). The agreement is aimed at deploying and commercializing HSS Orthopedic Care Pathways on Zimmer Biomet's mymobility with Apple Watch, which is a first-of-its-kind remote-care management platform.

Price Performance

Shares of the company have gained 63.4% in the past year compared with the industry’s 26.2% rise and the S&P 500’s 53.6% growth.

Zacks Rank & Stocks to Consider

Currently, Zimmer Biomet carries a Zacks Rank #4 (Sell).

Some other better-ranked stocks from the broader medical space are Hill-Rom Holdings, Inc. HRC, IDEXX Laboratories, Inc. IDXX and Align Technology, Inc. ALGN.

Hill-Rom’s long-term earnings growth rate is estimated at 7.3%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

IDEXX’s long-term earnings growth rate is estimated at 15.8%. It currently carries a Zacks Rank #2.

Align Technology’s long-term earnings growth rate is estimated at 19.8%. It currently sports a Zacks Rank #1.

Bitcoin, Like the Internet Itself, Could Change Everything

Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.

Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.

See 3 crypto-related stocks now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Align Technology, Inc. (ALGN) : Free Stock Analysis Report

HillRom Holdings, Inc. (HRC) : Free Stock Analysis Report

IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report

To read this article on Zacks.com click here.